As for AEs of atezolizumab in combination with bevacizumab therapy, the pooled incidence of all-grade AEs was 83%, and the common all-grade AEs with an incidence of more than 10% were as follows: AST increase (31%), ALT elevation (24%), proteinuria (24%), hypertension (24%), fatigue (23%), thrombocytopenia (20%), appetite loss (19%), pyrexia (17%), peripheral edema (17%), pruritus (13%), nausea (10%), rash (10%), and a blood bilirubin increase (10%). This evidence concerns the gene GPT and edema.